While the former Biden administration showcased the Inflation Reduction Act as a key victory in the fight over high drug ...

The Economic Survey 2024-25 says on a global pedestal, India has successfully established itself as one of the top 20 medical ...

SaSPinjara Life Sciences sees Indian pharma boosting capability in high-demand therapeutics: Nandita Vijayasimha, Bengaluru Saturday, February 1, 2025, 08:00 Hrs [IST] SaSPinjara ...

New Delhi: Drug major Glenmark Pharmaceutical has got the go-ahead from the Subject Expert Committee (SEC) functional under ...

Economic Survey 2025 calls for systematic deregulation, focus on R&D: Our Bureau, New Delhi Friday, January 31, 2025, 15:30 Hrs [IST] Projecting a growth of around 6.3 to 6.8 per ...

The pre-budget document tabled in Parliament on Friday said that the government must focus on a multi-pronged approach with stricter FSSAI labelling norms, higher GST, and awareness campaigns to curb ...

JMP Securities maintained a positive outlook on Kalvista Pharmaceuticals Inc (NASDAQ:KALV), reiterating a Market Outperform ...

The Economic Survey 2024-25 emphasises the need for increased innovation, new drug development, and biopharmaceutical ...

Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on KalVista Pharmaceuticals (KALV).Invest with Confidence: ...

There is a need to focus on innovation, new drug development and biopharmaceuticals as spending on research and development still lags behind global leaders, ...

Discover top must-watch Kannada thrillers like 'Ulidavaru Kandanthe', 'Lucia', and more. Stream them now on Netflix, Prime ...